FutureMeds Investigator Network

Access our vast investigator network

Leverage the expertise of FutureMeds 220+ experienced investigators and benefit from higher trial & data quality, efficiency, and reliability.

"At FutureMeds, we work with patients across all indications, offering diverse treatment options for oncological, metabolic, and other diseases. Physicians partnering with us find valuable opportunities for themselves and their patients. We take pride in our high number of medical investigators and referrals, providing sponsors with direct access to patients and invaluable expertise."

FutureMeds Clinical Research Site Operations

Wojciech Szczepanik

EVP of Site Operations

Connect

Access to all possible specialisations

FutureMeds covers all possible specializations, including oncology and CNS, through established relationships with over 220 reliable principal investigators who can deliver at the highest standards.

Strong network and collaboration

All specialisations with proven track record

Arrange a meeting

Enhanced Risk Mitigation

Unlike trial naive or one off investigators, FutureMeds Investigators can anticipate and mitigate risks based on previous experiences. This leads to fewer unexpected issues and delays, ensuring timelines are met.

Proactive risk management

Reduced trial delays

Arrange a meeting

Adaptive Trial Management

FutureMeds PIs have comprehensive knowledge, access to tools and infrastructure that enables them to deliver more streamlined, cost-effective trials with consistent high-quality data collection.

Efficient study start-up

Cost-effective operations

Arrange a meeting

Trial oversight by highly experienced FutureMeds principal investigators

220+

Investigators with 5-15 years of experience

2,060+

Trials conducted by FutureMeds investigator network

22.5k

Patients enrolled in FutureMeds clinical trial studies

Access to primary physicians as sub-investigators

1,300+ physicians and other healthcare professionals partner with FutureMeds to provide a more holistic care option to their patients, increase patient access to research and shape trial delivery